Bristol-Myers Squibb

(BMY) - Get Report

moved higher in the premarket session following FDA approval for its schizophrenia treatment Abilify.

The shares were recently up 4.4% to $25.10.

The drug, which will be comarketed with Otsuka, gained conditional FDA approval in September, and will join

Eli Lilly's

(LLY) - Get Report

Zyprexa,

Johnson & Johnson's

(JNJ) - Get Report

Risperdal and

Pfizer

(PFE) - Get Report

Geodon among FDA-approved schizophrenia treatments.

Some analysts think Abilify could eventually bring in $2 billion a year for Bristol-Myers, welcome revenue for a company that has recently struggled with a shrinking new drug pipeline and a regulatory probe of its inventory practices.